High level serum IL-6 predicts occurrence of TA-TMA.

IF 4.5 2区医学 Q1 HEMATOLOGY Bone Marrow Transplantation Pub Date : 2024-11-27 DOI:10.1038/s41409-024-02478-x

Renzhi Zheng, Lin Li, Jianzhi Zhao, Diange Jin, Jimin Shi, Yanmin Zhao, Jian Yu, Xiaoyu Lai, Lizhen Liu, Huarui Fu, Congxiao Zhang, Jia Shen, He Huang, Yi Luo, Yishan Ye

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

高水平的血清 IL-6 可预测 TA-TMA 的发生。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Bone Marrow Transplantation 医学-免疫学

CiteScore

8.40

自引率

8.30%

发文量

337

审稿时长

6 months

期刊介绍： Bone Marrow Transplantation publishes high quality, peer reviewed original research that addresses all aspects of basic biology and clinical use of haemopoietic stem cell transplantation. The broad scope of the journal thus encompasses topics such as stem cell biology, e.g., kinetics and cytokine control, transplantation immunology e.g., HLA and matching techniques, translational research, and clinical results of specific transplant protocols. Bone Marrow Transplantation publishes 24 issues a year.

期刊最新文献

High level serum IL-6 predicts occurrence of TA-TMA. A multifactorial risk scoring system for the prediction of early relapse in CMML patients with allo-HSCT: a nationwide representative multicenter study. Utilization of hematopoietic cell transplantation and cellular therapy technology in Europe and associated Countries. Using the 2022 activity survey data to correlate with economic and demographic factors. A report from the EBMT. The BLIND study: blinatumomab and DLI approach for management of B-ALL relapse after allogeneic stem cell transplantation. A multicentric Italian experience. Measurable residual disease testing and allogeneic hematopoietic cell transplantation for AML: adapting Pre-MEASURE to clinical practice.